DIAGNOSING PROSTATE CANCER RELAPSE
    1.
    发明申请
    DIAGNOSING PROSTATE CANCER RELAPSE 审中-公开
    诊断前列腺癌相关

    公开(公告)号:US20120326025A1

    公开(公告)日:2012-12-27

    申请号:US13575903

    申请日:2011-01-28

    IPC分类号: H01J49/26

    CPC分类号: G01N33/57434 G01N2800/54

    摘要: The invention discloses the use of at least one substance selected from the group consisting of Phosphatidylcholine with diacyl residue sum C24:0 (PC aa C24:0); Phosphatidylcholine with diacyl residue sum C40:3 (PC ae C40:3); Phosphatidylcholine with diacyl residue sum C40:4 (PC ae C40:4); Lysophosphatidylcholine with acyl residue sum C26:0 (lysoPC a C26:0); Lysophosphatidylcholine with acyl residue sum C6:0 (lysoPC a C6:0); 13(S)-hydroxy-9Z,11E-octadecadienoic acid (13S-HODE); 12(S)-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid (12S-HETE); 15(S)-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid (15S-HETE); Leukotriene B4 (LTB4); Prostaglandin E2 (PGE2); Prostaglandin D2 (PGD2); 7α-Hydroxycholesterol (7aOHC); 7-Ketocholesterol (7KC); 5β,6β-Epoxycholesterol (5b,6b,EPC); 5g302,6g302-Epoxycholesterol (5a,6a,EPC); and 4β-Hydroxycholesterol (4BOHC); for prognosticating relapse of a prostate cancer (PCa) in a sample of a body fluid or a tissue sample of a PCa patient.

    摘要翻译: 本发明公开了使用选自由二酰基残基和C24:0(PCaa C24:0)组成的组的至少一种物质; 具有二酰基残基总数C40:3的磷脂酰胆碱(PC ae C40:3); 具有二酰基残基的磷脂酰胆碱总数C40:4(PC ae C40:4); 酰基残基总数为C26:0的溶血磷脂酰胆碱(lysoPC a C26:0); 具有酰基残基的溶血磷脂酰胆碱和C6:0(溶血糖素a C6:0); 13(S) - 羟基-9Z,11E-十八碳二烯酸(13S-HODE); 12(S) - 羟基-5Z,8Z,10E,14Z-二十碳四烯酸(12S-HETE); 15(S) - 羟基-5Z,8Z,11Z,13E-二十碳四烯酸(15S-HETE); 白三烯B4(LTB4); 前列腺素E2(PGE2); 前列腺素D2(PGD2); 7α-羟基胆固醇(7aOHC); 7-酮胆固醇(7KC); 5&bgr;,6&bgr; - 环氧胆固醇(5b,6b,EPC); 5g302,6g302-环氧胆固醇(5a,6a,EPC); 和4&bgr; - 羟基胆固醇(4BOHC); 用于预测PCa患者体液或组织样品中前列腺癌(PCa)的复发。

    Diagnostic marker for cancer
    3.
    发明申请
    Diagnostic marker for cancer 审中-公开
    癌症诊断标志物

    公开(公告)号:US20070172900A1

    公开(公告)日:2007-07-26

    申请号:US10589487

    申请日:2005-02-16

    IPC分类号: G01N33/574 A61K39/395

    摘要: The invention relates to the use of various proteins as diagnostic markers for cancerous diseases. In particular, the use of the annexin A3 protein is preferred. Preferably an increased regulation of annexin A3 is analysed in comparison to controls. The invention also relates to the use of active substances for producing a medicament used in the treatment of cancer, said substances influencing the activity and/or abundance of various characteristic proteins.

    摘要翻译: 本发明涉及各种蛋白质作为癌性疾病的诊断标记物的用途。 特别地,优选使用膜联蛋白A3蛋白。 与对照相比,优选分析增加的膜联蛋白A3的调节。 本发明还涉及活性物质用于制备用于治疗癌症的药物的用途,所述药物影响各种特征性蛋白质的活性和/或丰度。